Dear C3 Community, We’re pleased to share an update on the progress on the C3-led clinical trial, “STAR-BD01,” which will use Tumour Infiltrating Lymphocyte (TIL) therapy to treat people living with biliary tract cancers in Canada. This trial represents hope for many people across Canada, and we remain committed to keeping you informed with transparency to manage expectations as we move forward. From the very beginning, our goal with this trial has remained clear: to deliver

Dear C3 Community,   We’re excited to share updates on the C3-led clinical trial, “ STAR-BD01” , which will use Tumor Infiltrating Lymphocytes (TIL) therapy to treat biliary tract cancers. We know this trial represents hope for many, and we’re committed to keeping you informed about our progress, challenges, and next steps.   TIL therapy is a form of personalized cell therapy that has shown promising results across various cancer types, including cholangiocarcinoma. Currently